1.Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc.
People living with rare and devastating diseases are our Guiding Star. We believe it is our responsibility to listen to, understand, and change the lives of patients and those who work tirelessly to help them.
We continue to deepen our understanding of rare disease, which began with our pioneering work in complement biology. This knowledge allows us to innovate and evolve into new areas, where there is great unmet need and opportunity to help patients and families fully live their best lives.
We’ve delivered transformative medicines for people with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD), generalized Myasthenia Gravis (gMG), hypophosphatasia (HPP), and lysosomal acid lipase deficiency (LAL-D).
Medicine
Conditions We Treat
aHUS
FXa Bleeds
gMG
HPP
LAL-D
NMOSD
PNH
Contact no:+1 475-230-2596
Address:121 Seaport Blvd, Boston, MA 02210, United States
Website:https://alexion.com/
2.Paratek Pharmaceuticals Inc
Positive outcomes. Positive patient stories. These are our priorities at Paratek Pharmaceuticals. We develop transformative solutions for patients with infectious diseases and other difficult to treat conditions, and we believe that with the right people, the right knowledge and the right drug, we can make a difference in patients’ lives.
To create positive stories for patients, physicians and caregivers based on trust and integrity. To accomplish this, our employees work hard to turn every day decisions into everyday triumphs that advance our technology and strengthen Paratek.
To be a leading independent biopharmaceutical company providing novel life-saving products for life-threatening diseases or other public health threats.
PRODUCTS
NUZYRA®
AMR is a Global Health Threat
Antimicrobial Resistance (AMR) is life-threatening, costly and present in every country in the world.
Drug-resistant infections cost the US an annual $20 billion in excess healthcare costs and $35 billion in lost productivity. According to recent research, it’s estimated that up to 160,000 in US die from antibiotic resistance per year and almost three-quarters of a million people around the globe annually; by 2050 that could grow to 10 million every year if the trend isn’t slowed.
Contact no:: +1 617-807-6600
Address:: 75 Park Plaza 4th floor, Boston, MA 02116, United States
Website:https://www.paratekpharma.com/
3.Vertex Pharmaceuticals
Vertex creates new possibilities in medicine to cure diseases and improve people’s lives. We work with leading researchers, doctors, public health experts and other collaborators who share our vision for transforming the lives of people with serious diseases, their families and society.
Understanding CF
Lungs IconLungs Icon
Vertex’s Cystic Fibrosis Journey
Patient Advocacy
Vertex CF Community and Grant Programs
The Vertex and CookTracks Podcast Series
Contact no:+1 617-341-6100
Address: Drydock Ave, Boston, MA 02210, United States
Website: https://www.vrtx.com/
4.Symbiosis Pharmaceutical Services
We created our purpose-built facility in Stirling, Scotland, specifically designed with biologic and small molecule production capabilities in mind to support biotech and speciality pharmaceutical companies worldwide that require small-scale injectable products.Differing from most CMOs, from the day our operations commenced we offered rapid access to manufacturing slots and quick release of drug products to ensure tight timelines are successfully met. Naturally, this has been a real hit with our clients.
Our core manufacturing capability takes place within an MHRA-licensed facility, which enables our team to fill bulk volumes under 100 litres, including products that require aseptic liquid filling and lyophilisation, such as:
Biologics including mAb’s, proteins, peptides and RNA
Cytotoxic, cytostatic and high potent APIs including ADCs
Small molecules
Contact no:+44 1786 220000
Address: 625 Massachusetts Ave 2nd Floor, Cambridge, MA 02139, United States
Website:https://www.symbiosis-pharma.com/
5.Acetylon Pharmaceuticals Inc
We are a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation.
We have the brightest people in the industry and believe that their diverse experiences and perspectives help to bring out our best ideas, drive innovation and achieve transformative business results.
Each day, our employees around the world work together for patients – patients are at the center of everything we do. They inspire us. They are the reason we come to work each day.
We are proud of the advancements we have made in oncology, hematology, immunology and cardiovascular disease, and we are dedicated to helping patients prevail over serious diseases through our diverse and promising pipeline and new scientific platforms. We are pursuing therapies at the forefront of scientific discovery with the goal of bringing an exciting new generation of life-changing treatments to patients. We aspire to be at the center of a vibrant healthcare innovation ecosystem, where academic research centers, biotech and biopharma companies all contribute to continued scientific advancement.
Contact no:1 617-245-1300
Address:70 Fargo St, Boston, MA 02210, United States
Website:https://www.bms.com/
6.Keryx Biopharmaceuticals, Inc.
Since our founding in 2007, we’ve put tenacity and innovation to work to develop unique therapeutics that have the potential to set new standards of care for people living with kidney disease. We have emerged as a leader with deep roots in the renal community. Today, we are a fully integrated biopharmaceutical company with both an experienced nephrology-focused commercial team and a robust development organization.
We have a commercial product approved and marketed in the United States and a late-stage product candidate. Our lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which completed global Phase 3 program for the treatment of anemia due to chronic kidney disease.
As part of our mission, we’re working to address complications of kidney disease and we currently market AURYXIA® (ferric citrate) in the U.S. for its two approved indications:
Important Safety Information
CONTRAINDICATION
AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis
WARNINGS AND PRECAUTIONS
Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
Risk of Overdose in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children
Contact no: +1 617-466-3500
Address:1 Marina Park Drive, Boston, MA 02210, United States
Website:https://akebia.com/
7.Atea Pharmaceuticals, Inc.
Discovering and rapidly advancing potentially transformative antiviral therapies.
Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases.
Leveraging the power of our medicinal chemistry expertise and purine nucleotide prodrug platform, we are focused on discovering, optimizing, and rapidly advancing novel drug candidates for viral targets such as SARS CoV-2.
RNA VIRUSES
The prevalent cause of severe human viral diseases.
Single-stranded positive-sense RNA viruses account for a large number of clinically serious global pathogens and are the cause of many potentially life-threatening diseases: coronaviruses, including SARS-CoV-2, the virus responsible for COVID-19, dengue, yellow fever, Ebola, Zika, West Nile, encephalitis viruses, hepatitis C, and RSV.
The activity of a key viral enzyme, RNA-dependent RNA polymerase, also known as RNA polymerase, is required for replication and propagation of these viruses. The structure of this enzyme is highly conserved across RNA viruses. Most viral RNA polymerases have been identified on the basis of comparative sequence analysis, but it is important to know that viral genome replication is initiated by two different and distinct mechanisms.
Contact no:+1 857-284-8891
Address:125 Summer St, Boston, MA 02110, United States
Website:https://ateapharma.com/
8..Novartis Pharmaceuticals
Our strategy is to build a leading, focused medicines company powered by advanced therapy platforms and data science.
Chief Talent and People Solutions Officer Tripti Jha’s mother prioritized her learning in a rural region of India with limited opportunities for girls.
Our purpose is to reimagine medicine to improve and extend people’s lives. We use innovative science and technology to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.
Navigate Novartis
Patients & Caregivers
Healthcare Professionals
Investors
Media
Society & ESG
Contact no: +1 617-577-0285
Address: 181 Massachusetts Ave, Cambridge, MA 02139, United States
Website:https://www.novartis.com/
9.Dicerna Pharmaceuticals, Inc
At Dicerna, we create medicines that selectively silence the genes that cause disease using RNA interference, or RNAi. We are leaders in RNAi, harnessing the potential of this powerful and complex process to create medicines that can enhance the health and extend the lives of patients with rare diseases and common diseases with a genetic component.
Genes play a primary role in thousands of diseases. At Dicerna, we use our proprietary GalXC™ platform to develop safe and potent RNAi therapies that target and suppress genes. We are advancing our growing pipeline of product candidates designed to inhibit the genetic causes of diseases and disorders that affect the liver, kidney, cardiovascular system and central nervous system.
Pipeline
Nedosiran (formerly DCR-PHXC)
RG6346 (formerly DCR-HBVS)
Belcesiran (formerly DCR-A1AT)
Collaborative Programs
Clinical Trials
Contact no:+1 617-621-8097
Address: 87 Cambridge Park Dr, Cambridge, MA 02140, United States
Website:https://dicerna.com/
10.Pieris Pharmaceuticals, Inc
Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and immuno-oncology multi-specifics tailored for the tumor microenvironment. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies.
Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalin proteins have repeatedly delivered drug candidates binding to a broad spectrum of therapeutic targets.
Products
Candidate Targets Indication Partner Our Commercial
Rights Discovery Preclinical IND-
enabling Phase I Phase IIa
PRS-343 4-1BB/HER2
Bispecific Immuno-Oncology n/a Worldwide
Discovery Phase completed
Pre-Clinical Phase completed
IND-enabling Phase completed
Phase 1 in progress
Phase 2 not started
PRS-344 4-1BB/PD-L1
Bispecific Immuno-Oncology Servier U.S. Rights; Ex-U.S. Royalties
Discovery Phase completed
Pre-Clinical Phase completed
IND-enabling Phase in progress
Phase 1 not started
Phase 2 not started
PRS-352 n.d./n.d.
Contact no:: +1 857-246-8998
Address:: 255 State St 9th floor, Boston, MA 02109, United States
Website:https://www.pieris.com/